AXGN
Axogen, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$44.23
−2.33%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$44.94
From 52W high−14.50%
Volume1.12M
Market cap$2.60B
P/E (TTM)—
P/S (TTM)10.3x
Div yield—
Key dataSep 18, 2026
Open
$44.94
From 52W high
−14.50%
Volume
1.12M
Market cap
$2.60B
ValuationView details →
P/E (Fwd)
76.3x
EV/EBITDA
−170.6x
P/E (TTM)
—
RSI (14)
45.9
MomentumView details →
1D Return
−2.33%
YTD Return
+37.89%
SummaryUpdated Jun 1, 2026
AxoGen, Inc. (NASDAQ:AXGN) is a medical device company founded in 1986 and headquartered in Alachua, Florida. The company specializes in developing and marketing surgical solutions for peripheral nerve repair and reconstruction. AxoGen has evolved from its early days to become a leading provider of biologically-based nerve repair products, serving surgeons across multiple specialties including plastic reconstruction, orthopedic hand surgery, and oral and maxillofacial surgery. The company operates primarily in the United States but has expanded internationally to Canada, Germany, the United Kingdom, South Korea, and other markets.
Similar companies
Latest newsMore news →
Axogen, Inc. announced the pricing of an underwritten public offering of 4,910,000 shares of its common stock at $42.50 per share, expecting gross proceeds of approximately $208.7 million.10d agoAxogen entered into a definitive agreement to acquire BioCircuit Technologies, adding the FDA-approved NerveTape device for sutureless peripheral nerve repair.10d ago